CellAegis Announces First Patients Enrolled in U.S. SHIELD Pivotal Clinical Trial
TORONTO, April 10, 2018 (GLOBE NEWSWIRE) -- CellAegis Devices Inc. ("CellAegis" or the "Company"), a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for acute and chronic cardiovascular conditions, today announced enrollment of the first patients in a U.S. clinical trial ("SHIELD") of its autoRIC® device.
The autoRIC® device automatically delivers remote ischemic conditioning ("RIC") to provide a non-invasive, cardio-protective therapy shown to reduce heart damage during heart attacks and certain cardiovascular procedures.
SHIELD is a 500 patient, multi-center, randomized, controlled single-blind clinical trial designed to evaluate the safety and effectiveness of the autoRIC® device to attenuate myocardial injury, as measured by the validated biomarker cardiac Troponin I ("cTnl") levels in patients undergoing elective percutaneous coronary intervention ("PCI"). Patients that are scheduled for either an elective PCI procedure, or a diagnostic catheterization procedure that may be followed with stenting, will be enrolled in the study across up to 15 research sites in the U.S. and Canada. The primary efficacy outcome of this trial is to show a statistically significant reduction in the prevalence of ischemia-reperfusion injury to the myocardium in patients using the autoRIC® device compared to patients using a placebo device. Patients will be exited from the study after completion of their 30-day post-procedure follow-up.
"We are pleased to start enrolling patients in this clinical trial," commented Roxana Mehran, MD, principal investigator for SHIELD, Professor of Medicine and Director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Weiner Cardiovascular Institute at Mount Sinai School of Medicine. "While there have been tremendous advancements in cardiac care over the past several years, there is no question that significant unmet medical need remains. We believe this trial has been designed to clearly demonstrate whether the autoRIC® can reduce heart damage during PCI. This study will answer the question of whether the autoRIC®device; which is easy to use and implement, will have clinical utility in this patient population."
The autoRIC® device is approved by Health Canada and in Europe, where it is being used in multiple large investigator-sponsored trials to further assess effectiveness in reducing adverse events after a heart attack. A positive SHIELD study will be used to support CellAegis's premarket submission to the U.S. Food and Drug Administration (FDA) for US commercialization of the autoRIC® device.
"There are approximately 1 million elective PCI procedures performed annually in the US, in patients with ischemic heart disease and elevations of troponin resulting from the procedure, that have been shown to result in poorer clinical outcomes," said Rocky Ganske, Chief Executive Officer, CellAegis. "Enrollment of the first patients in this U.S. pivotal clinical trial represents an important step forward in the autoRIC® clinical development program. Our current expectations are to complete the study in the third quarter of 2018."
RIC is a noninvasive therapeutic that uses four cycles of limb occlusion and reperfusion to protect the myocardium against ischemia-reperfusion injury. RIC is a promising adjunctive treatment to PCI in the prevention of ischemic-reperfusion injury and minimization of postinfarction heart failure in ST-elevation myocardial infarction ("STEMI") patients. Previous proof-of-concept clinical studies using RIC before or during a major ischemic event have demonstrated improvements in surrogate markers of ischemia, such as increased myocardial salvage and reduced infarct size, in a variety of clinical scenarios including acute STEMI, elective PCI, and coronary artery bypass grafting surgery. Furthermore, in patients with STEMI, RIC before PCI has been shown to reduce the incidence of contrast-induced acute kidney injury and has prevented acute kidney injury in patients undergoing cardiopulmonary bypass-assisted cardiac surgery.
The autoRIC® device is designed to provide RIC to adult patients over 18 years of age undergoing cardiothoracic surgery, interventional cardiothoracic procedures or patients with evolving myocardial infarction. The technology is intended for use in hospital and ambulance settings as directed by healthcare professionals. The autoRIC® device is CE Marked, and Health Canada approved, and is currently limited to investigational use in the United States.
About CellAegis Devices
CellAegis Devices, headquartered in Toronto, Canada, is the world leader in automated remote ischemic conditioning. The company has patented and developed the non-invasive autoRIC® device, which delivers RIC therapy to patients with acute and chronic cardiovascular conditions. The autoRIC® device has CE Mark and Health Canada approvals for treatment during heart attacks, cardiothoracic or surgical procedures. Investigator sponsored clinical research studies for chronic conditions such as heart failure and stroke are also underway. The autoRIC® device was developed from the clinical work of clinicians and researchers at Toronto's world-renowned Hospital for Sick Children.
This press release may contain forward-looking statements identified by words such as "expects", "anticipates", "will" and similar expressions, which reflect CellAegis' current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. The forward-looking statements are made as of the date of this press release and CellAegis does not undertake and is not obligated to publicly update such forward looking statements to reflect new information, subsequent events or otherwise, except as required by law.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CellAegis Devices Inc. via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Tenaris Announces 2018 First Quarter Results26.4.2018 23:02 | Pressemelding
Tenaris S.A. / Tenaris Announces 2018 First Quarter Results . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. The financial and operational information contained in this press release is based on unaudited consolidated condensed interim financial statements presented in U.S. dollars and prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standard Board ("IASB") and in conformity with IFRS as adopted by the European Union ("EU"). Additionally, this press release includes non-IFRS alternative performance measures i.e., EBITDA, Net cash / debt and Free Cash Flow. See exhibit I for more details on these alternative performance measures. LUXEMBOURG, April 26, 2018 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE:TS) (BAE:TS) (BMV:TS) (MILAN:TEN) ("Tenaris") today announced its results for the quarter ended March 31, 2018 in comparison with its results
Atico Produces 5.48 Million Pounds of Cu and 2,825 Ounces of Au in First Quarter 201826.4.2018 22:35 | Pressemelding
VANCOUVER, British Columbia, April 26, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the "Company" or "Atico") (TSX-V:ATY) (OTC:ATCMF) announces its operating results for the three months ended March 31, 2018 from its El Roble mine. Production for the quarter totaled 5.48 million pounds of copper and 2,825 ounces of gold in concentrates, an increase of 9% and 11% for copper and gold, respectively, over the same period in 2017. "We are very pleased to report our strongest operating quarter to date while maintaining steady state production levels and a robust start towards our 2018 operational objectives" said Fernando E. Ganoza, CEO. "For the remainder of the year, the Company will continue focusing on the regional and mine vicinity exploration programs with rigs currently drilling on surface and underground." First Quarter Operational Highlights Production of 5.48 million pounds of copper contained in concentrates; an increase of 9% over Q1 2017. Production of 2,825 ounces of gold
Cloudflare Grows Network by Nearly 30 Percent in First Quarter26.4.2018 22:00 | Pressemelding
The company announced three new products and a major collaboration as part of giant quarter SAN FRANCISCO, April 26, 2018 (GLOBE NEWSWIRE) -- Cloudflare, the leading Internet performance and security company, today announced record network growth in the first quarter of 2018. The company added 32 new cities, growing its network to 151 points of presence globally. Cloudflare now protects more than 8 million domains, websites, APIs, mobile applications, and anything connected to the Internet. "At Cloudflare's core is its network, which we've built to be flexible, efficient, and able to perform any task in any given location," said Matthew Prince, co-founder and CEO of Cloudflare. "In this last quarter, we grew our network at record pace, bringing our network closer to everyone on earth. This means that we're able to roll out products at a global scale for users everywhere." Today's announcement caps off a strong quarter for Cloudflare. The company announced three major new products in th
VITEC's EZ TV Video Wall Solution Wins Best of Show Award at the 2018 NAB Show26.4.2018 19:00 | Pressemelding
VITEC's EZ TV Video Wall Solution Wins Best of Show Award at the 2018 NAB Show SUNNYVALE, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- VITEC, a worldwide leader in advanced video encoding and streaming solutions, today announced that the new EZ TV video wall processor, available within the award-winning EZ TV IPTV and Digital Signage Platform, was recognized with a Best of Show Award at the 2018 NAB Show from Sound & Video Contractor (SVC) magazine. Evaluated by a panel of industry experts, the Best of Show Award winners were selected based on innovation, feature set, cost efficiency, and performance in serving the industry. VITEC's video wall solution is designed to simplify deployment and management of projects involving IPTV, digital signage, and video wall content, while delivering a breathtaking visual experience. The new EZ TV video wall processors are 100 percent hardware-based, feature low-latency native playback of IPTV streams up to 4K, and support interactive content, video, a
Inspiration in Receipt of Crypto Currency Proposal26.4.2018 16:54 | Pressemelding
TORONTO, April 26, 2018 (GLOBE NEWSWIRE) -- Inspiration Mining Corporation ("Inspiration" or the "Corporation") (CSE:ISM) is pleased to announce that it is contemplating upon the request of Compassion Cannabis that it is allowed to accept crypto currency for settlement for any transactions that occur. The logic is that it would make for easy settlement in any jurisdiction. The Company is not adverse to this proposal, but must perform its due diligence and will table the matter at the AGM. Compassion Cannabis is an Ontario Corp., which has expertise to forward various facets of the explosive new market of the marijuana industry, including but not limited to the "Vape" market and dispensary centers for the industry. We believe this will be an extremely lucrative space with tremendous demand in the medical cannabis industry. For further information, please contact Randy Miller, Chief Executive Officer of the Corporation, at tel: 416-842-9000, www.inspirationmining.com The CSE has not revi
SNOMED International Announces Brazil as its 33rd Member26.4.2018 15:12 | Pressemelding
London, United Kingdom, April 26, 2018 (GLOBE NEWSWIRE) -- Brazil's Ministry of Health and SNOMED International announce that as of April 1, 2018, Brazil has joined the organization as SNOMED International's thirty-third Member. With SNOMED CT already used in various parts of the country, Brazil joined SNOMED International to support nationwide health system transformation as a foundational element of its ehealth Strategy, digiSUS. As outlined in this national strategy, the SUS Monitoring and Evaluation Department of Brazil's Ministry of Health is responsible overall for governance of the National Electronic Health Strategy and its related evaluation and development. Demonstrated through its membership in SNOMED International, Brazil has defined SNOMED CT as the chosen international reference terminology for use in its clinical systems supporting the national ehealth strategy. SNOMED CT is the world's most comprehensive health terminology. Founded in 2007 by nine charter nations, SNOME
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom